David Ferri-Rufete

Dr. David Ferri-Rufete

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in AJO International
Verified
Journal Article
Open access
DFDavid Ferri-Rufete
David Ferri-Rufete
LBL Baleta-Riera
L Baleta-Riera
DCDídac Casas-Alba
Dídac Casas-Alba
SBS Balsells
S Balsells
ALA Llorca-Cardeñosa
A Llorca-Cardeñosa
AMAf Martínez-Monseny
Af Martínez-Monseny

25 September 2023 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
DFDavid Ferri-Rufete
David Ferri-Rufete
ALAitor López-González
Aitor López-González
DCDídac Casas-Alba
Dídac Casas-Alba
DCDaniel Cuadras
Daniel Cuadras
FPFrancesc Palau
Francesc Palau
AMAntonio Federico Martínez-Monseny
Antonio Federico Martínez-Monseny

18 March 2026 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
DFDavid Ferri-Rufete
David Ferri-Rufete
JBJuan Carretero Bellón
Juan Carretero Bellón
FMFredy Hermógenes Prada Martínez
Fredy Hermógenes Prada Martínez
FCFederico Xavier Zarco Contreras
Federico Xavier Zarco Contreras
Joan Sanchez-de-ToledoJoan Sanchez-de-Toledo
Joan Sanchez-de-Toledo
Background: Thromboembolic complications remain a significant cause of morbidity following the Fontan procedure, driven by the unique haemodynamics of the Fontan circulation. Case summary: We present a case of a 14-year-old patient with single-ventricle physiology who underwent an extracardiac Fontan procedure. Post-operatively, he developed low cardiac output requiring extracorporeal membrane oxygenation (ECMO) support. Despite successful weaning from ECMO, hepatomegaly, pleural effusion, and ascites persisted. Further investigation revealed a significant thrombus within the Fontan conduit. Due to the high risks associated with systemic thrombolysis and repeat cardiac surgery, these treatment options were not pursued. Instead, an innovative approach utilizing a device specifically engineered for thrombus extraction in the pulmonary arteries was used. The conduit thrombus was completely extracted without complications, and the patient recovered rapidly and was discharged 2 weeks later. Discussion: This case highlights the potential complications following Fontan surgery and the importance of timely, tailored new therapeutic interventional procedures in fragile patients with complex congenital heart diseases.

6 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IMInés Martínez-Saludes
Inés Martínez-Saludes
CRCristina Ruiz-Herguido
Cristina Ruiz-Herguido
Joan Sanchez-de-ToledoJoan Sanchez-de-Toledo
Joan Sanchez-de-Toledo
DFDavid Ferri-Rufete
David Ferri-Rufete
SMSilvia Montserrat
Silvia Montserrat
RLRaquel Luna-López
Raquel Luna-López
Patients with congenital heart disease (CHD) represent a special healthcare challenge due to their high complexity, which accompanies them throughout all life stages. Consequently, this population faces increased morbidity and mortality rates, often linked to hemodynamic shifts in pulmonary flow or cardiac output. These risks are further compounded by potential arrhythmias and heart failure decompensation, which may lead to the progressive progression toward advanced stages of the disease. Unfortunately, standard outpatient follow-up is often not capable of responding to the continuous monitoring needs presented by these patients and their families. This selective review frames information on the wearable devices that have emerged as a key solution for continuous and remote monitoring. Beyond clinical tracking, research is increasingly focusing on their role in assessing physical activity—a critical determinant of health outcomes in the CHD population. This review examines the existing literature on wearable technology in both pediatric and adult patients while also addressing the current limitations that hinder their integration into routine clinical practice.